From a value perspective, I'd say $30 would be high end. rayze got bought for 4.1b US off a small subset of an indication, albeit they were in P3(which they've had to pause due to supply issues).
if cu67 shows significantly superior efficacy with a better safety profile, this may take a large share of the mCRPC market that is moving further up the line in therapy. This is not accounting for their diagnostics or other therapy.
from a realistic perspective, I'm not sure if it'd get to $30, but stranger things have happened(afterpay).
CU6 - Media and Industry News, page-544
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.20 |
Change
0.190(2.71%) |
Mkt cap ! $2.305B | |||
| Open | High | Low | Value | Volume |
| $7.12 | $7.34 | $6.95 | $5.698M | 788.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 16776 | $7.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.27 | 197 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |